PIP5K1A polyclonal (N-term), anti-human

Background:
Overexpression of phosphatidylinositol phosphate 5-kinase alpha (PIP5KIalpha), which synthesizes PIP2, suppresses apoptosis, whereas a kinase-deficient mutant does not. Protection by the wild-type PIP5KIalpha isaccompanied by decreases in the generation of activated caspases and of caspase 3-cleaved PARP. Protection is not mediated through PIP3 or Akt activation. An anti-apoptotic role for PIP(2) is substantiated by the finding that PIP5KIalpha is cleaved by caspase 3 during apoptosis, and cleavage inactivates PIP5KIalpha in vitro. Mutation of the P(4) position (D279A) of the PIP5KIalpha caspase 3 cleavage consensus prevents cleavage in vitro, and during apoptosis in vivo. Significantly, the caspase 3-resistant PIP5KIalpha mutant is more effective in suppressing apoptosis than the wild-type kinase. PIP2 is a direct regulator of apical and effector caspases in the death receptor and mitochondrial pathways, and PIP5KIalpha inactivation contributes to the progression of apoptosis.

Other Names:
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha, PIP5K1-alpha, PtdIns(4)P-5-kinase 1 alpha, 68 kDa type I phosphatidylinositol 4-phosphate 5-kinase alpha, Phosphatidylinositol 4-phosphate 5-kinase type I alpha, PIP5KIalpha, PIP5K1A

Target/Specificity:
This PIP5K1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 19-50 amino acids from the N-terminal region of human PIP5K1A.

Antigen Region:
19-50

Antigen Type: Synthetic Peptide

Gene Name: PIP5K1A (HGNC:8994)
Gene ID: 8394
Primary Accession: Q99755
NCBI Accession: NP_001129108.1;NP_001129109.1;NP_001129110.1;NP_003548.1
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.